Evidence map›Paper›PMID 41949976›Full record

ReviewCanadian respiratory journal2026

Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.

Yalei Wang, Jiacheng Wu, Qian Ma, Hao Chen, Erha Lama, Yulu Yang, Jianwu Huang, Changhu Liu, Xiaofei Ni, Zhihua Qiu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yalei WangDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0009-7423-8293
Jiacheng WuDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0006-3102-0604
Qian MaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0008-2380-3865
Hao ChenDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0003-0975-6197
Erha LamaDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0004-2327-7026
Yulu YangDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0004-6073-2083
Jianwu HuangDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0009-2577-1956
Changhu LiuDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0003-6565-3985
Xiaofei NiDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0009-0003-8591-1320
Zhihua QiuDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0000-0003-2701-4763
Zihua ZhouDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, hust.edu.cn.ORCID 0000-0003-3513-5020

Funding

National Natural Science Foundation of China 82070378National Natural Science Foundation of China 82270534National Natural Science Foundation of China 82370352
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease characterized by vascular remodeling, endothelial dysfunction, and chronic inflammation. Despite existing targeted therapies, long-term outcomes remain poor, underscoring the need for more effective treatment. This review summarizes recent advancements in PAH therapy, emphasizing the integration of conventional medicine of the key pathways with nanoparticle-mediated drug delivery systems (nano-DDS), transforming growth factor beta/bone morphogenetic protein receptor type II, tyrosine kinase-based interventions, immunotherapies targeting inflammation and immune imbalance, and emerging molecular targets, including NOTCH3/HES-5 and E-selectin. Nano-DDS has improved drug bioavailability and targeting, opening new therapeutic possibilities. This article also discusses innovative approaches, such as endothelial-like progenitor cell-based cell therapy and the ETRQβ-002 vaccine. Future advancements in PAH treatment may result from the integration of conventional drugs, nanotechnology, and immunotherapy through multidisciplinary efforts.

Indexed as

Hypertension, PulmonaryBone Morphogenetic Protein Receptors, Type IIDrug Delivery SystemsHumansImmunotherapyMolecular Targeted TherapyNanoparticle Drug Delivery SystemTransforming Growth Factor betaBone Morphogenetic Protein Receptors, Type IINanoparticle Drug Delivery SystemTransforming Growth Factor betaE-selectinimmunotherapymolecular-targeted therapynanoparticlespulmonary arterial hypertensionreceptor NOTCH3

Identifiers

PMID41949976
PMCPMC13060647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.